Condition
Prostate Cancer Castration-resistant Prostate Cancer
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (2)
P 1 (2)
Trial Status
Recruiting3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07145255Phase 1RecruitingPrimary
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07156045Early Phase 1RecruitingPrimary
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
NCT07298239Early Phase 1RecruitingPrimary
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04108247Phase 1UnknownPrimary
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
Showing all 4 trials